Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present end of study results for the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") at the 52nd Annual Meeting of the American Society of Hematology on Sunday, December 5, 2010 in Orlando, Florida.
The presentation is scheduled for Sunday, December 5, 2010 during the "Lymphoma: Chemotherapy, excluding Pre-Clinical Models" session that will be held from 6:00 p.m.-8:00 p.m. Eastern time. The presentation, abstract #2833, is titled, "Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): End of Study Results." The abstract is available at www.hematology.org.
Cancer cases in the US continued to be underdiagnosed during the second year of the COVID-19 pandemic